Vistagen Therapeutics, Inc. 8-K

What Happened Vistagen Therapeutics, Inc. (VTGN) filed an 8-K on February 6, 2026 disclosing that the Nasdaq Listing Qualifications Staff issued a notice stating the company's common stock has not met Nasdaq’s $1.00 minimum closing bid requirement based on the last 30 consecutive business days. The notice does not have an immediate effect on the listing.

Key Details

• Filing date: February 6, 2026; notice issued due to the closing bid price being below $1.00 for the past 30 consecutive business days.
• Cure requirement: VTGN must have a closing bid of at least $1.00 for 10 consecutive business days within the 180-calendar day period from Feb 3, 2026 to Aug 3, 2026 to regain compliance.
• Possible extension: If compliance is not regained by August 6, 2026, Nasdaq may grant a second 180-calendar day period only if VTGN meets the market value of publicly held shares and all other initial listing standards (other than the minimum bid price).
• Risk if not cured: Failure to regain compliance within the allotted periods (including any Nasdaq extensions) could lead Nasdaq to provide notice that VTGN’s common stock will be subject to delisting.
• Report signed by President & CEO Shawn K. Singh.

Why It Matters This notice signals a material listing risk: if VTGN does not meet the $1.00 bid-price requirement within the specified timeframes, its stock could be moved off the Nasdaq Capital Market, which can reduce liquidity, investor visibility and complicate trading. Investors should monitor VTGN’s share price, company disclosures and any measures the company may take to address the deficiency.